STAT+: Cytokinetics drug improves blood flow in patients with inherited form of heart disease

Cytokinetics said Monday that its experimental drug demonstrated statistically significant improvements in blood flow for patients with an inherited form of heart disease — a result that compares favorably to a competing heart drug recently acquired by Bristol Myers Squibb.

In a small, mid-stage clinical trial, 13 of 14 patients, or 93%, treated with a higher dose of the Cytokinetics drug, called CK-274, achieved improvement in blood flow to a target level where they no longer met the threshold for being diagnosed with their disease — obstructive hypertrophic cardiomyopathy, or HCM. No concerning or unexpected side effects were reported.

Continue to STAT+ to read the full story…

STAT+: Cytokinetics drug improves blood flow in patients with inherited form of heart disease

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top